Pfizer Analysts Cut Their Forecasts Following Q3 Results


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


Pfizer Inc (NYSE:PFE) reported a loss for the third quarter on Tuesday.

Pfizer reported a quarterly adjusted EPS loss of 17 cents versus a consensus loss of 32 cents, down from an EPS income of 67 cents in Q2 and $1.78 a year ago. The company reported a 42% slump in Q3 sales to $13.23 billion, down from $22.64 billion a year ago, beating the consensus of $12.72 billion.

Pfizer shares gained 0.2% to trade at $30.61 on Wednesday.

These analysts made changes to their price targets on Pfizer following earnings announcement.

  • Morgan Stanley slashed the price target on Pfizer from $39 to $37. Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating.
  • Barclays lowered the price target on Pfizer from $35 to $34. Barclays analyst Carter Gould maintained an Equal-Weight rating.

Also Check This Out: Top 3 Consumer Stocks That Could Sink Your Portfolio In Q4


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: EarningsNewsPrice TargetIntraday UpdateMarketsAnalyst RatingsTrading IdeasPT Changes